TB500
TB-500
Primary Application: Cellular Migration, Angiogenesis, and Systemic Tissue Repair
Fundamental Information
-
Amino Acid Sequence: N-Acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ)
-
Chemical Formula: C38H68N10O14
-
Molecular Weight: 889.02 Daltons
-
Classification: Synthetic fragment of the endogenous protein Thymosin Beta-4
Detailed Overview
TB-500 is a synthetic peptide that represents the most biologically active region of Thymosin Beta-4, a natural protein found in nearly all human and animal cells. While Thymosin Beta-4 is a large protein of 43 amino acids, TB-500 is a specialized 7-amino acid fragment (residues 17-23) specifically engineered to maintain the parent protein’s regenerative and anti-inflammatory properties while being small enough to move more effectively through the body’s tissues.
The primary mechanism of TB-500 involves its interaction with actin, a vital protein that forms the “skeletal” structure of cells. TB-500 binds to monomeric G-actin and promotes the formation of new cellular pathways, a process known as cellular migration. By essentially unlocking the ability of cells to move, TB-500 allows repair-oriented cells, such as fibroblasts and keratinocytes, to travel to the site of an injury much faster than they could otherwise. This makes the peptide a leading subject for research into the accelerated healing of tendons, ligaments, and muscle fibers.
Beyond just moving cells, TB-500 is heavily studied for its role in angiogenesis—the growth of new blood vessels from existing ones. By increasing the expression of Vascular Endothelial Growth Factor (VEGF), it helps re-establish blood flow to damaged areas that are normally “blood-poor,” such as joint connective tissues. In animal models, such as BALB/c mouse studies, TB-500 administration has demonstrated the ability to significantly speed up wound closure and reduce the formation of restrictive scar tissue (fibrosis), resulting in more flexible and functional tissue during recovery.
Scientific References
-
Esposito S, et al. “Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500.” Drug Testing and Analysis. 2012.
-
Philp D, et al. “The actin binding site on thymosin beta-4 promotes angiogenesis.” The FASEB Journal. 2003.
-
Tchanque-Fossuo CN, et al. “A systematic review of the biological effects of Thymosin beta-4 on wound healing.” International Wound Journal. 2017.
